Mometasone Furoate in Non-Allergic Rhinitis: A Real-Life Italian Study

Background: In order to evaluate the efficacy of intranasal mometasone furoate in patients with non-allergic rhinitis (NAR), a real-life, observational, prospective study is performed. Methods: Thirty-one patients (age 18–64 years) receive intranasal (mometasone furoate, 200 µg b.i.d. for 15 consecu...

Full description

Saved in:
Bibliographic Details
Published in:Journal of personalized medicine 2022-07, Vol.12 (7), p.1179
Main Authors: Rizzi, Angela, Parrinello, Giuseppe, De Corso, Eugenio, Tricarico, Laura, Centrone, Michele, Di Rienzo, Alessia, Laface, Chiara, Passali, Giulio Cesare, Cadoni, Gabriella, Inchingolo, Riccardo, Paludetti, Gaetano, Galli, Jacopo, Nucera, Eleonora
Format: Article
Language:English
Subjects:
Allergens
Allergic rhinitis
Allergies
Cellular biology
Drug dosages
Endoscopy
Medical imaging
Nose
Olfaction
Pathophysiology
Patients
Precision medicine
Quality of life
Respiration
Rhinitis
Steroids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: In order to evaluate the efficacy of intranasal mometasone furoate in patients with non-allergic rhinitis (NAR), a real-life, observational, prospective study is performed. Methods: Thirty-one patients (age 18–64 years) receive intranasal (mometasone furoate, 200 µg b.i.d. for 15 consecutive days per month for 6 consecutive months), plus isotonic nasal saline. The cytologic pattern of local inflammation, nasal airflow, through peak nasal inspiratory flow (PNIF), quality of life (QoL), through the rhinitis quality of life questionnaire (RQLQ), the sinonasal outcome test (SNOT-22), the short-form 36-item health survey (SF-36v2), and the combined symptom medication score (CSMS), and, finally, olfactory function, through Sniffin’ sticks-16 identification test (SSIT-16), are evaluated at baseline and after treatment. Results: NARNE is the most frequent cytological pattern (48% of the total sample). The therapeutic response shows improvement in olfactory function and QoL. Conclusions: The results of this study confirm that intranasal mometasone furoate is an effective treatment for patients with NAR.
ISSN:2075-4426
2075-4426
DOI:10.3390/jpm12071179